Haaretz EnglishHealth
Teva Pharmaceutical Receives FDA Approval for Monthly Schizophrenia Injection Weltruza
Summarized from Haaretz English by baba
Center-leftNeutral tone
Teva Pharmaceutical has received FDA approval for Weltruza, a new monthly injection for schizophrenia patients. This is the second product from Teva's partnership with Medincell, following Uzedy's approval last year. Teva expects to launch Weltruza in the U.S. soon, with analysts noting the potential for improved patient adherence. The deal could yield Medincell up to $112 million plus royalties.
The story in 6 lines · by baba
- Teva Pharmaceutical received FDA approval for its monthly schizophrenia injection, Weltruza.
- Weltruza is the second U.S.-approved product from Teva's partnership with Medincell.
- The drug utilizes Medincell's long-acting injectable technology for extended medication release.
- Analysts believe long-acting antipsychotics can improve treatment adherence for chronic conditions.
- Medincell could receive up to $112 million in milestone payments and royalties from the deal.
- Teva shares rose 2% and Medincell shares increased 16.9% following the announcement.
Haaretz English publishes in English. The key points are summarized above. Read Haaretz English’s full report from the link at the top of the page.
Mentioned
